New inhaled therapy for scarred lungs enters first human tests
Disease control
Recruiting now
This early-stage study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body handles the drug. About 145 participants will receive either the drug…
Phase: PHASE1 • Sponsor: Agomab Spain S.L. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC